ATE267015T1 - Verbindungen und verfahren zur behandlung von krebs - Google Patents

Verbindungen und verfahren zur behandlung von krebs

Info

Publication number
ATE267015T1
ATE267015T1 AT95933071T AT95933071T ATE267015T1 AT E267015 T1 ATE267015 T1 AT E267015T1 AT 95933071 T AT95933071 T AT 95933071T AT 95933071 T AT95933071 T AT 95933071T AT E267015 T1 ATE267015 T1 AT E267015T1
Authority
AT
Austria
Prior art keywords
compounds
methods
treating cancer
cancer
treating
Prior art date
Application number
AT95933071T
Other languages
English (en)
Inventor
Chung K Chu
Yung-Chi Cheng
Original Assignee
Univ Georgia Res Found
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Univ Georgia Res Found, Univ Yale filed Critical Univ Georgia Res Found
Application granted granted Critical
Publication of ATE267015T1 publication Critical patent/ATE267015T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT95933071T 1994-09-06 1995-09-05 Verbindungen und verfahren zur behandlung von krebs ATE267015T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE267015T1 true ATE267015T1 (de) 2004-06-15

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95933071T ATE267015T1 (de) 1994-09-06 1995-09-05 Verbindungen und verfahren zur behandlung von krebs

Country Status (31)

Country Link
US (3) US6063787A (de)
EP (2) EP0781136B1 (de)
JP (1) JP3979662B2 (de)
KR (1) KR100374477B1 (de)
CN (3) CN1827108A (de)
AP (1) AP783A (de)
AT (1) ATE267015T1 (de)
AU (1) AU704977B2 (de)
BG (1) BG63122B1 (de)
BR (1) BR9508886A (de)
CA (1) CA2199117C (de)
CZ (1) CZ297873B6 (de)
DE (1) DE69533066T2 (de)
DK (1) DK0781136T3 (de)
ES (1) ES2219666T3 (de)
FI (1) FI970918A (de)
HU (1) HUT77172A (de)
IL (1) IL115156A (de)
IS (1) IS2011B (de)
MY (1) MY121548A (de)
NO (1) NO313268B1 (de)
NZ (1) NZ335013A (de)
OA (1) OA10473A (de)
PL (2) PL188359B1 (de)
PT (1) PT781136E (de)
RO (1) RO118748B1 (de)
RU (1) RU2168995C2 (de)
SI (1) SI0781136T1 (de)
SK (1) SK284564B6 (de)
WO (1) WO1996007413A1 (de)
ZA (1) ZA957483B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
CN1307421C (zh) 1997-08-08 2007-03-28 塞米得肿瘤学美国公司 克服生物及化学治疗抗性的方法与组合物
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DE69900841T2 (de) 1998-01-23 2002-10-02 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
BR9908270A (pt) 1998-02-25 2004-06-29 Univ Emory 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos
CA2366012A1 (en) * 1999-03-29 2000-10-05 Shire Biochem Inc. Methods of treating leukemia
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US6583149B1 (en) 1999-09-24 2003-06-24 Biochem Pharma Inc. Method for the treatment or prevention of viral infection using nucleoside analogues
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
EP1600452A3 (de) 1999-11-12 2008-09-10 Pharmasset, Inc. Herstellung von 2'-Deoxy-L-Nukleoside
PL361310A1 (en) * 2000-10-13 2004-10-04 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
DE60234577D1 (de) 2001-03-23 2010-01-14 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
US20030027799A1 (en) * 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
AU2002336864B2 (en) * 2001-11-02 2006-08-17 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
PT1448186E (pt) * 2001-11-19 2009-03-24 Medigene Ag Medicamento para o tratamento de doenças virais da pele e doenças tumorais
JP4299779B2 (ja) 2002-06-21 2009-07-22 エルジー エレクトロニクス インコーポレーテッド ビデオデータの再生を管理するためのデータ構造を有する記録媒体
MXPA04002365A (es) 2002-06-21 2004-11-22 Lg Electronics Inc Medio de grabacion que tiene estructura de datos para manejar la reproduccion de datos de video grabados en el mismo.
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
WO2004001751A1 (en) 2002-06-24 2003-12-31 Lg Electronics Inc. Recording medium having data structure including navigation control information for managing reproduction of video data recorded thereon and recording and reproducing methods and apparatuses
CA2459086C (en) 2002-06-28 2013-08-13 Lg Electronics Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
RU2347284C2 (ru) 2002-10-14 2009-02-20 Эл Джи Электроникс Инк. Носитель записи со структурой данных для управления воспроизведением записанного на нем множества аудиопотоков и способы и устройства записи и воспроизведения
CN100479051C (zh) 2002-10-15 2009-04-15 Lg电子有限公司 具有管理多路图形流重现的数据结构的记录介质及记录和重现方法和装置
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
EP1604356A4 (de) 2003-02-28 2009-12-16 Lg Electronics Inc Aufzeichnungsmedium mit datenstruktur zur verwaltung der random/shuffle-wiedergabe von darauf aufgezeichneten videodaten sowie verfahren und vorrichtungen zur aufzeichnung und wiedergabe
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
AU2004281525B2 (en) 2003-10-09 2010-01-28 Aresus Pharma GmbH The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
CN103735560A (zh) 2005-06-07 2014-04-23 耶鲁大学 使用克来夫定和替比夫定治疗癌症和其它病症或疾病状态的方法
US7951788B2 (en) * 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
CN101534835B (zh) * 2006-09-01 2012-05-30 佐治亚大学研究基金会 用于癌症的L-OddC的前药
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备***药物中的应用
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备***药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CN110168092A (zh) * 2016-12-28 2019-08-23 特朗斯吉有限公司 溶瘤病毒和治疗分子
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
EP0206497B1 (de) * 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutische Nucleoside und deren Herstellung
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
IN164556B (de) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
NZ223990A (en) * 1987-03-24 1990-08-28 Nycomed As Acylated 2',3'-dideoxynucleosides and pharmaceutical compositions
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
EP0375329B1 (de) * 1988-12-19 1995-05-31 The Wellcome Foundation Limited Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
SK279542B6 (sk) * 1991-03-06 1998-12-02 The Wellcome Foundation Limited U
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995018137A1 (en) * 1993-12-30 1995-07-06 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Also Published As

Publication number Publication date
IL115156A (en) 2000-07-16
JP3979662B2 (ja) 2007-09-19
KR970705393A (ko) 1997-10-09
WO1996007413A1 (en) 1996-03-14
ZA957483B (en) 1997-06-06
PL318971A1 (en) 1997-07-21
AP9700939A0 (en) 1997-04-30
CA2199117A1 (en) 1996-03-14
SK284564B6 (sk) 2005-06-02
NO971015L (no) 1997-03-05
CZ297873B6 (cs) 2007-04-18
BG101284A (en) 1998-03-31
NO313268B1 (no) 2002-09-09
CN1448142A (zh) 2003-10-15
KR100374477B1 (ko) 2003-06-19
SK28197A3 (en) 1997-09-10
CN1111409C (zh) 2003-06-18
JPH10506385A (ja) 1998-06-23
DE69533066D1 (de) 2004-06-24
FI970918A0 (fi) 1997-03-04
AU704977B2 (en) 1999-05-13
US7262213B2 (en) 2007-08-28
CN1251680C (zh) 2006-04-19
EP0781136A1 (de) 1997-07-02
CN1160351A (zh) 1997-09-24
PL189288B1 (pl) 2005-07-29
DK0781136T3 (da) 2004-08-02
US6063787A (en) 2000-05-16
BR9508886A (pt) 1997-12-30
OA10473A (en) 2002-04-08
NZ335013A (en) 2000-07-28
US20050261320A1 (en) 2005-11-24
AP783A (en) 1999-11-17
AU3586295A (en) 1996-03-27
US8076347B2 (en) 2011-12-13
US20080171758A1 (en) 2008-07-17
IL115156A0 (en) 1995-12-31
ES2219666T3 (es) 2004-12-01
HUT77172A (hu) 1998-03-02
CZ63397A3 (en) 1997-07-16
PT781136E (pt) 2004-09-30
IS4434A (is) 1997-03-04
FI970918A (fi) 1997-05-02
NO971015D0 (no) 1997-03-05
DE69533066T2 (de) 2005-06-02
EP0781136B1 (de) 2004-05-19
MY121548A (en) 2006-02-28
RO118748B1 (ro) 2003-10-30
CN1827108A (zh) 2006-09-06
PL188359B1 (pl) 2005-01-31
RU2168995C2 (ru) 2001-06-20
IS2011B (is) 2005-05-13
EP1468687A1 (de) 2004-10-20
SI0781136T1 (en) 2004-08-31
BG63122B1 (en) 2001-04-30
CA2199117C (en) 2006-04-11
EP0781136A4 (de) 1999-06-23

Similar Documents

Publication Publication Date Title
ATE267015T1 (de) Verbindungen und verfahren zur behandlung von krebs
DE69625690T2 (de) Verfahren zur vorbeugung und behandlung von allergien
DE69425372T2 (de) Verfahren zur behandlung endo-ostealer materialien
DE69331469D1 (de) Verfahren zur behandlung von abfällen
DE69730604D1 (de) Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen
ATE477270T1 (de) Verfahren und zusammensetzungen zur prävention und behandlung von anämie
DE69925266D1 (de) Verfahren und gerät zur behandlung von herzarhythmie
DE69112480D1 (de) Verfahren und Vorrichtung zur Behandlung von medizinischen Abfallstoffen.
DE69816070D1 (de) Verfahren zur Behandlung von Schredderstaub
DE69714828D1 (de) Verfahren zur Behandlung von Abfallstoffen
DE69426485T2 (de) Verfahren und System zur Behandlung von verunreinigtem Wasser
DE69417018T2 (de) Verfahren zur behandlung von teilchenmaterial
DE69600480D1 (de) Verfahren und vorrichtung zur behandlung von aggregat
DE69518824T2 (de) Verfahren zur behandlung von bremsscheiben
DE69702997T2 (de) Verfahren zur Behandlung von verunreinigtem Aluminiumoxid
DE69328615T2 (de) Verfahren zur behandlung von viehhaltungsgülle
DE69607559T2 (de) Verfahren zur Behandlung von Phenolteer
DE69706758D1 (de) Verfahren zur Behandlung von Polyolefin
DE59308384D1 (de) Verfahren zur Behandlung von Gülle
DE69510990T2 (de) Verfahren und Vorrichtung zur Behandlung von metallichem Material
DE69935858D1 (de) Verfahren und vorrichtung zur behandlung von scheiben
DE69535154D1 (de) Verfahren zur Behandlung von Textilmaterialien
DE69913051D1 (de) Verfahren zur Behandlung und Entsorgung von einer Epithio-Verbindung
DE69527792D1 (de) Verfahren und einrichtung zur behandlung von fluiden
DE69427897D1 (de) Verfahren zur Behandlung von kontaminierten Sedimenten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0781136

Country of ref document: EP

REN Ceased due to non-payment of the annual fee